116 related articles for article (PubMed ID: 38903193)
1. ExoDS: a versatile exosome-based drug delivery platform to target cancer cells and cancer stem cells.
Paul S; Bhagat S; Dash L; Mohapatra HD; Jena S; Verma SK; Dutta A
Front Bioeng Biotechnol; 2024; 12():1362681. PubMed ID: 38903193
[TBL] [Abstract][Full Text] [Related]
2. Targeted doxorubicin-loaded mesenchymal stem cells-derived exosomes as a versatile platform for fighting against colorectal cancer.
Bagheri E; Abnous K; Farzad SA; Taghdisi SM; Ramezani M; Alibolandi M
Life Sci; 2020 Nov; 261():118369. PubMed ID: 32882265
[TBL] [Abstract][Full Text] [Related]
3. Targeted delivery of doxorubicin to HER2 positive tumor models.
Gomari H; Forouzandeh Moghadam M; Soleimani M; Ghavami M; Khodashenas S
Int J Nanomedicine; 2019; 14():5679-5690. PubMed ID: 31413568
[TBL] [Abstract][Full Text] [Related]
4. Exosome-sheathed porous silica nanoparticle-mediated co-delivery of 3,3'-diindolylmethane and doxorubicin attenuates cancer stem cell-driven EMT in triple negative breast cancer.
Sarkar R; Biswas S; Ghosh R; Samanta P; Pakhira S; Mondal M; Dutta Gupta Y; Bhandary S; Saha P; Bhowmik A; Hajra S
J Nanobiotechnology; 2024 May; 22(1):285. PubMed ID: 38796426
[TBL] [Abstract][Full Text] [Related]
5. Exosome mimetics derived from bone marrow mesenchymal stem cells deliver doxorubicin to osteosarcoma
Wang J; Li M; Jin L; Guo P; Zhang Z; Zhanghuang C; Tan X; Mi T; Liu J; Wu X; Wei G; He D
Drug Deliv; 2022 Dec; 29(1):3291-3303. PubMed ID: 36352741
[TBL] [Abstract][Full Text] [Related]
6. Exosome mimetics derived from bone marrow mesenchymal stem cells ablate neuroblastoma tumor in vitro and in vivo.
Li M; Wang J; Guo P; Jin L; Tan X; Zhang Z; Zhanghuang C; Mi T; Liu J; Wang Z; Wu X; Wei G; He D
Biomater Adv; 2022 Nov; 142():213161. PubMed ID: 36308859
[TBL] [Abstract][Full Text] [Related]
7. Targeted cancer therapy using engineered exosome as a natural drug delivery vehicle.
Gomari H; Forouzandeh Moghadam M; Soleimani M
Onco Targets Ther; 2018; 11():5753-5762. PubMed ID: 30254468
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis.
Wei H; Chen F; Chen J; Lin H; Wang S; Wang Y; Wu C; Lin J; Zhong G
Int J Nanomedicine; 2022; 17():3483-3495. PubMed ID: 35959282
[TBL] [Abstract][Full Text] [Related]
9. Exosomal LncRNA-NEAT1 derived from MIF-treated mesenchymal stem cells protected against doxorubicin-induced cardiac senescence through sponging miR-221-3p.
Zhuang L; Xia W; Chen D; Ye Y; Hu T; Li S; Hou M
J Nanobiotechnology; 2020 Oct; 18(1):157. PubMed ID: 33129330
[TBL] [Abstract][Full Text] [Related]
10. Impact of doxorubicin-loaded ferritin nanocages (FerOX) vs. free doxorubicin on T lymphocytes: a translational clinical study on breast cancer patients undergoing neoadjuvant chemotherapy.
Sevieri M; Andreata F; Mainini F; Signati L; Piccotti F; Truffi M; Bonizzi A; Sitia L; Pigliacelli C; Morasso C; Tagliaferri B; Corsi F; Mazzucchelli S
J Nanobiotechnology; 2024 Apr; 22(1):184. PubMed ID: 38622644
[TBL] [Abstract][Full Text] [Related]
11. Multifunctional nanotherapeutics for intracellular trafficking of doxorubicin against breast cancer.
Kurmi BD; Patel P; Paliwal R; Kumar P; Paliwal SR
Nanomedicine (Lond); 2023 Aug; 18(19):1261-1279. PubMed ID: 37721134
[TBL] [Abstract][Full Text] [Related]
12. Platelet extracellular vesicles are efficient delivery vehicles of doxorubicin, an anti-cancer drug: preparation and in vitro characterization.
Wu YW; Lee DY; Lu YL; Delila L; Nebie O; Barro L; Changou CA; Lu LS; Goubran H; Burnouf T
Platelets; 2023 Dec; 34(1):2237134. PubMed ID: 37580876
[TBL] [Abstract][Full Text] [Related]
13. A Nanodrug Consisting Of Doxorubicin And Exosome Derived From Mesenchymal Stem Cells For Osteosarcoma Treatment In Vitro.
Wei H; Chen J; Wang S; Fu F; Zhu X; Wu C; Liu Z; Zhong G; Lin J
Int J Nanomedicine; 2019; 14():8603-8610. PubMed ID: 31802872
[TBL] [Abstract][Full Text] [Related]
14. Milk derived colloid as a novel drug delivery carrier for breast cancer.
Hayashi M; Silanikove N; Chang X; Ravi R; Pham V; Baia G; Paz K; Brait M; Koch WM; Sidransky D
Cancer Biol Ther; 2015; 16(8):1184-93. PubMed ID: 26046946
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Exosome Release Sensitizes U937 Cells to PEGylated Liposomal Doxorubicin.
Hekmatirad S; Moloudizargari M; Moghadamnia AA; Kazemi S; Mohammadnia-Afrouzi M; Baeeri M; Moradkhani F; Asghari MH
Front Immunol; 2021; 12():692654. PubMed ID: 34149737
[TBL] [Abstract][Full Text] [Related]
16. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy.
Tian Y; Li S; Song J; Ji T; Zhu M; Anderson GJ; Wei J; Nie G
Biomaterials; 2014 Feb; 35(7):2383-90. PubMed ID: 24345736
[TBL] [Abstract][Full Text] [Related]
17. AS1411 aptamer-functionalized exosomes in the targeted delivery of doxorubicin in fighting colorectal cancer.
Hosseini NF; Amini R; Ramezani M; Saidijam M; Hashemi SM; Najafi R
Biomed Pharmacother; 2022 Nov; 155():113690. PubMed ID: 36099793
[TBL] [Abstract][Full Text] [Related]
18. Exosome-mediated transfer of long noncoding RNA H19 induces doxorubicin resistance in breast cancer.
Wang X; Pei X; Guo G; Qian X; Dou D; Zhang Z; Xu X; Duan X
J Cell Physiol; 2020 Oct; 235(10):6896-6904. PubMed ID: 31994191
[TBL] [Abstract][Full Text] [Related]
19. Mononuclear phagocyte system blockade improves therapeutic exosome delivery to the myocardium.
Wan Z; Zhao L; Lu F; Gao X; Dong Y; Zhao Y; Wei M; Yang G; Xing C; Liu L
Theranostics; 2020; 10(1):218-230. PubMed ID: 31903116
[No Abstract] [Full Text] [Related]
20. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
